PSRC Abstract Supplement <0.001) during index admission. 90-Day readmission rate was 19.5% for non-flaps, 26.7% for local flaps, and 37.5% for free flaps (p-value <0.001). Adjusted mean total cost at 90-days was $23,690 for non-flaps, $55,126 for local flaps and $69,495 for free flaps (p-value <0.001). These trends were corroborated by results from the ICD9 cohort which included 43,769 patients, of which 595 were free flaps, 592 were local flaps, and 103 were both.
PURPOSE:
In the 2015 US Transgender Survey, 97% of transmen reported either previously having undergone, or being interested in undergoing gender mastectomy (otherwise known as top surgery). Despite this overwhelming interest in, as well as frequent anecdotal reports of improvements in, psychosocial functioning and patient reported outcomes (PROs) following this procedure, there is a dearth of prospective data supporting these observations. Existing PRO studies have largely been limited by lack of preoperative assessments, cross-sectional or retrospective designs, use of ad hoc questionnaires, small patient populations, or by their failure to evaluate a comprehensive range of domains. As part of a prospective study assessing the effects of gender mastectomy on PROs, we evaluated preoperative psychosocial functioning, anxiety, depression, and body image in transmen seeking these procedures.
METHODS:
In this prospective study, adult transmen presenting to a university-based plastic surgery clinic for gender-affirming chest reconstruction are being recruited for study participation. Surveys are completed at two time points: pre-operatively and six-months post-operatively. The panel includes demographic questions; the Patient Health Questionnaire-9 (PHQ-9) assessing depression; the Generalized Anxiety Disorder 7 Item Scale (GAD-7); the Body Image Quality of Life Index (BIQLI); and chest-specific body image items from the BREAST-Q and BODY-Q. All instruments have been previously validated. In this initial analysis, preoperative responses were scored and compared to available general population norms.
RESULTS:
From November, 2017 to November 2018, a total of 77 transmen have been enrolled and successfully completed the preoperative survey. Fifty-seven patients (74.0%) screened positive for mild to severe depression (mean sum score = 8.86, SD 6.06). Preoperatively, transmen reported significantly worse depression compared to cis-men in general (population mean sum score = 2.7), t(75) = 8.85, 95% CI (7.47, 10.24), p < 0.0001. Additionally, 55 patients (71.4%) screened positive for mild to severe anxiety (mean sum score = 8.8, SD 5.55). The mean transman reported significantly worse anxiety (t(74) = 9.5754, 95% CI (7.52, 10.08), p < 0.0001) and body image (t(67) = -5.71, 95% CI (-20.85, -9 .48), p < 0.0001), than the mean cis-male (population mean sum score = 2.66 and 1.10, respectively). BIQLI mean sum score was, on average, -14.84, SD 23.49.
CONCLUSIONS:
Overall, transmen presenting for top surgery had significantly higher levels of depression and anxiety, compared with population norms. This is consistent with known elevated levels of depression and anxiety in the trans community, but has yet to be documented in preoperative patients. Compared to age-matched peers, transmen also had significantly poorer body image. In our study, this pre-operative cohort presented with significant psychosocial distress, demonstrating the need to evaluate the impact of gender mastectomy on these measures post-operatively. In its next phase, our study will be assessing these results. PURPOSE: Current management of melanoma focuses on excision with the potential for lymph node evaluation depending on factors such as Breslow depth and ulceration status. The value of sentinel lymph node biopsy (SLNB) is well established in providing prognostic information, as patients with positive sentinel lymph nodes have worse survival outcomes. However, the option to pursue SLNB has not shown to provide any therapeutic benefits in improving survival. Anatomic specific locations for melanoma have been superficially evaluated, and to our knowledge there is no such literature surrounding SLNB in the perineum. Therefore, the purpose of this study is to evaluate the presence of a therapeutic benefit for SLNB and identify risk factors conferring reduced survival in patients with perineal melanoma.
METHODS:
The Surveillance, Epidemiology, and End Results (SEER) program is a large population-based cancer registry including survival data from millions of patients in the United States. The registry was used to generate patient data for analysis from 2004-2015. Inclusion criteria included melanoma of the vulva, penis, and scrotum; Breslow depth <0.80mm with ulceration and ≥0.80mm with or without ulceration; and documented SLNB with associated procedures, or no intervention performed. Outcomes of interest included disease-specific survival (DSS) and overall survival (OS), as well as patient and melanoma characteristics associated with reduced survival.
RESULTS:
Aggregates for DSS and OS were improved with implementation of SLNB. 5-year survival rates with SLNB were 54.7% and 49.9%, as compared to those without SLNB (44.9% and 38.0%) for DSS (p = 0.007) and OS (p = 0.001), respectively. Stratification by Breslow depth yielded significant OS advantage for >1.00-2.00mm (17.3% benefit p = 0.033) and >4.00mm (21.2% benefit p = 0.005) Breslow depth. Significant predictors of reduced survival included age greater than 75, Clark level IV-V, Breslow depth >4.00mm, positive ulceration status, melanoma subtype, and high mitotic rate.
CONCLUSION:
Although further randomized controlled trials are needed to establish definitive conclusions, our results suggest SLNB and resultant management may provide additional therapeutic benefits for patients with melanoma of the perineum. 
PURPOSE:
Iliac crest bone harvesting is routinely performed for patients undergoing alveolar bone grafting. Postoperative pain is one of the most common sources of graft site morbidity. Liposomal bupivacaine has been shown to decrease postoperative pain in patients receiving bunionectomy of hemorrhoidectomy. The role in pediatric patients undergoing alveolar bone grafting with an iliac crest donor site is unknown. The purpose of this study is to evaluate the efficacy of liposomal bupivacaine as compared to bupivacaine at the iliac crest hip donor site in pediatric patients.
METHODS: 38 patients undergoing iliac crest bone grafting were included in the study, with 21 and 17 patients receiving 0.25% bupivacaine and 1.30% liposomal bupivacaine respectively. Inclusion criteria included patients less than or equal to 18 years old. Outcomes of interest included reported pain scores every 4 hours for the first 24 hours, cumulative narcotic use, and length of stay. Postoperative steps were monitored using an activity tracker.
RESULTS:
The bupivacaine and liposomal bupivacaine groups showed no significant differences in age, weight,
